OPKO HEALTH, INC.
OPKNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $150.0M | $173.7M | $237.6M | $1.00B | $1.77B | $1.44B |
| Operating income | −$117.4M | −$152.1M | −$157.0M | −$226.3M | $18.8M | $57.7M |
| Net income | −$67.6M | −$81.8M | −$18.3M | −$328.4M | −$30.1M | $30.6M |
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | $2.40B | $2.47B |
| Total liabilities | $664.0M | $834.8M | $622.5M | $605.6M | $714.6M | $801.5M |
| Equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B | $1.67B |
| EPS (diluted) | $-0.10 | $-0.12 | $-0.25 | $-0.08 | $0.05 | $0.05 |
| Shares out. | 671.6M | 697.0M | 772.7M | 681.5M | 670.0M | 669.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −78.3%
- Net margin
- −45.1%
- Return on equity
- −5.3%
- Return on assets
- −3.5%
- Return on capital (ROCE)
- −6.6%
- Liabilities / assets
- 34.4%
- Debt / equity
- 0.52×
- Book value / share
- $1.89
- Revenue growth (YoY)
- −13.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.79distress
- Accruals / assets
- 5.7%moderate
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 1, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Not Yet Recruitingreadout ~2027-10Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
- Phase 1/2Not Yet Recruitingreadout ~2027-12Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Frost Phillip Md Et AlActivist (13D)Oct 1, 2025
- Rubric Capital Management LpPassive (13G)Jul 9, 2025
- Hsiao Jane Ph DActivist (13D)Apr 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 32.7M | 16.5 | -3.3% |
| Apr 30, 2026 | 33.8M | 12.7 | +2.4% |
| Apr 15, 2026 | 33.0M | 17.7 | -1.9% |
| Mar 31, 2026 | 33.6M | 10.9 | +2.6% |
| Mar 13, 2026 | 32.8M | 14.4 | +4.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsApr 28, 2026
- Director / officer changeMar 19, 2026
- Results of operationsFeb 26, 2026
- Results of operationsOct 29, 2025
- Regulation FD disclosure · Other material eventSep 15, 2025
- Results of operationsJul 31, 2025
- Director / officer changeMay 29, 2025
- Results of operationsApr 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.